Citable filing context

MRK filing events and research context

Server-rendered

MRK's research view summarizes recent SEC filing context, starting with other from May 28, 2026.

MRK filing events and research context
FiledItemContext
May 28, 2026otherMerck & Co. shareholders voted on directors, executive compensation, and other proposals at the Annual Meeting.
May 22, 2026debt_offeringMRK closed a $6 billion public offering of floating and fixed-rate notes.
Apr 30, 2026debt_offeringMerck registered multiple debt notes with varying interest rates and maturity dates.
Apr 30, 2026Guidance: non_gaap_effective_income_tax_rate23.50 to 24.50
Apr 30, 2026Guidance: non_gaap_eps5.04 to 5.16
Apr 30, 2026Guidance: non_gaap_eps_fx_impact0.10 to 0.10
May 4, 2026mda_quarterlyMerck reported a significant net loss of $(4,240) million for the first quarter ended March 31, 2026, a substantial decline from the $5,079 million net income in the prior year period. This downturn was primarily driven by a massive increase in Research and Development expenses, which surged to $12,592 million from $3,621 million year-over-year. Sales increased modestly to $16,286 million from $15,529 million. Other contributing factors to the loss included higher Cost of Sales, Selling, General and Administrative expenses, and Restructuring Costs, alongside a shift in Other (income) expense, net from a $35 million income to a $138 million expense. Basic earnings per share swung to a loss of $(1.72) from a profit of $2.01. Concurrently, the company repurchased 7,659,590 shares of common stock at an average price of $114.07 during the quarter, as part of a $10 billion share repurchase program approved in January 2025. Approximately $6,447 million remained available under this authorization as of quarter-end. No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors or executive officers.
Feb 24, 2026businessMerck & Co., Inc. operates as a global healthcare company across two reportable segments: Pharmaceutical and Animal Health. The Pharmaceutical segment, encompassing human health pharmaceuticals and vaccines, is primarily driven by its oncology blockbuster, Keytruda, which generated over $31 billion in 2025 sales. However, Keytruda faces significant U.S. Inflation Reduction Act (IRA) pricing pressure, expected to materially impact sales from 2029. The recently approved subcutaneous Keytruda Qlex extends patent protection until 2043. Gardasil/Gardasil 9 HPV vaccines are another major revenue contributor, with recent approvals for male indications. New products like Winrevair for pulmonary arterial hypertension and Capvaxive for pneumococcal disease are also contributing to growth. The Animal Health segment offers a wide range of veterinary pharmaceuticals, vaccines, and digital solutions, with Bravecto parasiticides being a key product. The company faces intense global competition and significant pricing pressures from government regulations, including the U.S. IRA impacting Januvia/Janumet from 2026/2027, EU reference pricing, and China's volume-based procurement leading to substantial price reductions. Key patent expirations for products like Januvia/Janumet (2026) and Gardasil (2028) necessitate continuous pipeline innovation and strategic product lifecycle management.

Source: SEC EDGAR filing text and events; period May 28, 2026; filed May 28, 2026.

Continue research

Keep researching MRK

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →
AMGN
AMGEN INC
$186.59B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →